These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 35814246)

  • 21. Analyzing the U.S. Post-marketing safety surveillance of COVID-19 vaccines.
    Albalawi OM; Alomran MI; Alsagri GM; Althunian TA; Alshammari TM
    Saudi Pharm J; 2022 Feb; 30(2):180-184. PubMed ID: 35002372
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neurological Events Reported after COVID-19 Vaccines: An Analysis of VAERS.
    Frontera JA; Tamborska AA; Doheim MF; Garcia-Azorin D; Gezegen H; Guekht A; Yusof Khan AHK; Santacatterina M; Sejvar J; Thakur KT; Westenberg E; Winkler AS; Beghi E;
    Ann Neurol; 2022 Mar; 91(6):756-71. PubMed ID: 35233819
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BAYESIAN LEARNING OF COVID-19 VACCINE SAFETY WHILE INCORPORATING ADVERSE EVENTS ONTOLOGY.
    Zhao B; Zhong Y; Kang J; Zhao L
    Ann Appl Stat; 2023 Dec; 17(4):2887-2902. PubMed ID: 39282096
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Statistical and Ontological Analysis of Adverse Events Associated with Monovalent and Combination Vaccines against Hepatitis A and B Diseases.
    Xie J; Zhao L; Zhou S; He Y
    Sci Rep; 2016 Oct; 6():34318. PubMed ID: 27694888
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vaccine adverse event reporting system (VAERS): Evaluation of 31 years of reports and pandemics' impact.
    Almadani OA; Alshammari TM
    Saudi Pharm J; 2022 Dec; 30(12):1725-1735. PubMed ID: 36601511
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The safety profile of COVID-19 vaccinations in the United States.
    Singh A; Khillan R; Mishra Y; Khurana S
    Am J Infect Control; 2022 Jan; 50(1):15-19. PubMed ID: 34699960
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults - United States, September 22, 2021-February 6, 2022.
    Hause AM; Baggs J; Marquez P; Myers TR; Su JR; Blanc PG; Gwira Baumblatt JA; Woo EJ; Gee J; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(7):249-254. PubMed ID: 35176008
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine - United States, December 14-23, 2020.
    ;
    MMWR Morb Mortal Wkly Rep; 2021 Jan; 70(2):46-51. PubMed ID: 33444297
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mining adverse events in large frequency tables with ontology, with an application to the vaccine adverse event reporting system.
    Zhao B; Zhao L
    Stat Med; 2023 May; 42(10):1512-1524. PubMed ID: 36791465
    [TBL] [Abstract][Full Text] [Related]  

  • 30. COVID-19 Vaccine Safety in Children Aged 5-11 Years - United States, November 3-December 19, 2021.
    Hause AM; Baggs J; Marquez P; Myers TR; Gee J; Su JR; Zhang B; Thompson D; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(5152):1755-1760. PubMed ID: 34968370
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Making US poison centers a part of the solution to the COVID-19 pandemic.
    Spyker DA; Bronstein AC; Weber JA
    Clin Toxicol (Phila); 2022 Jan; 60(1):102-114. PubMed ID: 34448649
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of the post-marketing safety profile between influenza and COVID-19 vaccines: An analysis of the vaccine adverse event reporting system.
    Al-Ahmari AK; AlAsmari A; AlKorbi A; Ahmed NJ; Almalki ZS; Alshehri AM; Albassam AA; Alem GM
    Saudi Pharm J; 2022 Aug; 30(8):1137-1142. PubMed ID: 35783675
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thromboembolic events in younger women exposed to Pfizer-BioNTech or Moderna COVID-19 vaccines.
    Sessa M; Kragholm K; Hviid A; Andersen M
    Expert Opin Drug Saf; 2021 Nov; 20(11):1451-1453. PubMed ID: 34264151
    [No Abstract]   [Full Text] [Related]  

  • 34. Ontology-Based Vaccine Adverse Event Representation and Analysis.
    Xie J; He Y
    Adv Exp Med Biol; 2017; 1028():89-103. PubMed ID: 29058218
    [TBL] [Abstract][Full Text] [Related]  

  • 35. OAE: The Ontology of Adverse Events.
    He Y; Sarntivijai S; Lin Y; Xiang Z; Guo A; Zhang S; Jagannathan D; Toldo L; Tao C; Smith B
    J Biomed Semantics; 2014; 5():29. PubMed ID: 25093068
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The COVID-19 Vaccines: A Description of Adverse Events of Reactions Reported in Kansas.
    Mills K; Tri A; Nilsen K
    Kans J Med; 2022; 15():39-47. PubMed ID: 35371387
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Urological complications after COVID 19 vaccine according to age, sex and manufacturer.
    Shim SR; Kim KT; Park E; Pyun JH; Kim JH; Chung BI
    World J Urol; 2023 Aug; 41(8):2255-2263. PubMed ID: 37400660
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Post-licensure surveillance of trivalent live attenuated influenza vaccine in adults, United States, Vaccine Adverse Event Reporting System (VAERS), July 2005-June 2013.
    Haber P; Moro PL; McNeil MM; Lewis P; Woo EJ; Hughes H; Shimabukuro TT
    Vaccine; 2014 Nov; 32(48):6499-504. PubMed ID: 25258101
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Frequency and Associations of Adverse Reactions of COVID-19 Vaccines Reported to Pharmacovigilance Systems in the European Union and the United States.
    Montano D
    Front Public Health; 2021; 9():756633. PubMed ID: 35186864
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ocular Complications after COVID-19 Vaccination, Vaccine Adverse Event Reporting System.
    Nyankerh CNA; Boateng AK; Appah M
    Vaccines (Basel); 2022 Jun; 10(6):. PubMed ID: 35746549
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.